616 related articles for article (PubMed ID: 32457743)
1. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
Lejeune M; Köse MC; Duray E; Einsele H; Beguin Y; Caers J
Front Immunol; 2020; 11():762. PubMed ID: 32457743
[TBL] [Abstract][Full Text] [Related]
2. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T-cell immunotherapy tackles blood cancers.
Brower V
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25838441
[No Abstract] [Full Text] [Related]
4. [Bispecific antibodies in onco-hematology: Applications and perspectives].
Barrière S; El-Ghazzi N; Garcia M; Guièze R
Bull Cancer; 2021 Oct; 108(10S):S195-S204. PubMed ID: 34920803
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs.
Foster LH; Lum LG
Expert Opin Biol Ther; 2019 Jul; 19(7):707-720. PubMed ID: 31081696
[TBL] [Abstract][Full Text] [Related]
6. Redirecting T cells to hematological malignancies with bispecific antibodies.
Velasquez MP; Bonifant CL; Gottschalk S
Blood; 2018 Jan; 131(1):30-38. PubMed ID: 29118005
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
8. Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies.
Burt R; Warcel D; Fielding AK
Hum Vaccin Immunother; 2019; 15(3):594-602. PubMed ID: 30380973
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibodies in haematological malignancies.
Viardot A; Bargou R
Cancer Treat Rev; 2018 Apr; 65():87-95. PubMed ID: 29635163
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials with blocked ricin immunotoxins.
O'Toole JE; Esseltine D; Lynch TJ; Lambert JM; Grossbard ML
Curr Top Microbiol Immunol; 1998; 234():35-56. PubMed ID: 9670611
[No Abstract] [Full Text] [Related]
11. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
12. T Cell-Activating Bispecific Antibodies in Cancer Therapy.
Trabolsi A; Arumov A; Schatz JH
J Immunol; 2019 Aug; 203(3):585-592. PubMed ID: 31332079
[TBL] [Abstract][Full Text] [Related]
13. [Cancer therapy using bispecific antibodies].
Kadowaki N
Rinsho Ketsueki; 2018; 59(10):1942-1947. PubMed ID: 30305495
[TBL] [Abstract][Full Text] [Related]
14. Influence of the bispecific antibody IgG subclass on T cell redirection.
Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.
Lussana F; Gritti G; Rambaldi A
J Clin Oncol; 2021 Feb; 39(5):444-455. PubMed ID: 33434063
[No Abstract] [Full Text] [Related]
16. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap.
Longhitano AP; Slavin MA; Harrison SJ; Teh BW
Blood Rev; 2021 Sep; 49():100810. PubMed ID: 33676765
[TBL] [Abstract][Full Text] [Related]
18. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
[TBL] [Abstract][Full Text] [Related]
19. [Bispecific antibodies in multiple myeloma].
Escure G; Manier S
Bull Cancer; 2021 Oct; 108(10S):S205-S212. PubMed ID: 34920804
[TBL] [Abstract][Full Text] [Related]
20. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
Einsele H; Borghaei H; Orlowski RZ; Subklewe M; Roboz GJ; Zugmaier G; Kufer P; Iskander K; Kantarjian HM
Cancer; 2020 Jul; 126(14):3192-3201. PubMed ID: 32401342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]